Chembio Diagnostics and its subsidiaries develop, manufacture, and commercialize point-of-care diagnostic tests that are used to detect and diagnose diseases. The company's product commercialization and product development activities are focused on infectious disease testing and technology collaborations. In infectious disease, the company is commercializing tests for human immunodeficiency virus and Syphilis, Zika virus, and developing tests for malaria, dengue virus, chikungunya virus, ebola, lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi, individually or as part of fever panel tests.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.